Lege Artis Medicinae

[Inhibitors of the renal sodium-glucose cotransporter: possible new drug in armamentarium of diabetologists]

BECHER Péter, PATAI Árpád, MÁJER Katalin

APRIL 20, 2012

Lege Artis Medicinae - 2012;22(04)

[An important aim of diabetologists is prescribing modern antidiabetic drugs with not only glucose lowering but also an insulin sensitivity increasing property with weight loss without hypoglycaemic episodes and with positive effects on the pancreatic β-cells. A selective inhibition of the renal sodium-glucose cotransporter 2 protein leads to glucosuria, reduces HbA1c and body weight without hypoglycaemias. This benefits can also moderate the cardiovascular risk in diabetic patients. At the moment this molecules are under examination in different phase clinical studies. It seems that the first drug from this group for the clinical use will be the molecule dapagliflozin. The main side effect may be a vulvovaginal mycotic infection.]



Further articles in this publication

Lege Artis Medicinae

[Surveillance-examination in the department of internal medicine of a frequented hospital]

SCHAREK Petra, LÉTAY Erzsébet, KATONA Katalin, RÓKUSZ László

[OBJECTIVES - In November 2010, wescreened patients admitted to the MilitaryHospital, 1st Department of Internal Medi-cine for meticillin-resistant Staphylococcusaureusand Gram-negative, extended spec-trum beta-lactamase producing bacteria.We detected the prevalence of colonisationor infection by these strains during hospitalstay. METHODS - We compiled a datasheet toregister patient data and results. Swabsfrom one of the anterior nares, the throatand the rectal area were taken at admissionand discharge after informed consent of thepatients. Microbiological samples wereprocessed by current microbiology guide-lines. RESULTS - During the one-month studyperiod, 134 adult patients were admitted,105 of who consented to the examination.At admission, six patients (5.7%) carriedmeticillin-resistant Staphylococcus aureusand five patients (4.76%) carried extendedspectrum β-lactamase producing Esche-richia coli. In one patient (0.95%) nosoco-mial extended spectrum β-lactamase pro-ducing Enterobacter cloacaewas identifiedin the rectal sample. In two patients (1.9%),rectal colonisation by Streptococcus pyogeneswas detected. CONCLUSIONS - Screening patients formeticillin-resistant Staphylococcus aureusin our department is important because ofthe high rate of patients returning to thehaematologic department, and consideringthat 4.5% of patients admitted to ourDepartment were transported to surgicaldepartments in 2010. It is particularlyimportant to determine the sampling location. The prevalence of rectal colonisatonby extended spectrum β-lactamase produc-ing bacteria was in accordance with international data. We didn’t detect infectionprovoked by the examined bacteria duringthe study period.]

Lege Artis Medicinae

[Twenty Years for Talents]

GYIMESI Ágnes Andrea

Lege Artis Medicinae

[Fulvestrant in late stage breast cancer]

BÍRÓ Mátyás, BÜDI László, AL-JAZAIRI Abdul Baki

Lege Artis Medicinae

[The Illness of Franz Kafka and his Perception of the World ]


Lege Artis Medicinae

[Implantable loop recorder for prevention of rare syncope]


All articles in the issue

Related contents

Lege Artis Medicinae

[Cost minimization analysis of basal insulin analogues in the treatment of type 2 diabetes]

MERÉSZ Gergő, TABÁK Gy. Ádám, KALÓ Zoltán

[INTRODUCTION - Basal insulin analogues are essential drugs for the treatment of type 2 diabetes mellitus. Basal insulin analogues have been shown to reduce the frequency of hypoglycaemia versus NPH insulin, and thus may be beneficial in the treatment of type 2 diabetes. Here we present a cost-minimisation analysis of basal insulin analogues, comparing insulin glargine and insulin detemir available in Hungary. METHODS - A literature review was conducted to identify randomized, controlled clinical trials with a duration of 12 weeks or more in which a direct comparison of insulin glargine and insulin detemir was made in patients with type 2 diabetes. In a meta-analysis of the eligible trials, the following endpoints were investigated: metabolic status, body weight, frequency of hypoglycaemia, insulin doses administered and the number of insulin injections required. If a high heterogeneity (I2>75%) was found, meta-regression was performed to identify the underlying reasons. The funder’s perspective was applied in the cost-minimization analysis by taking into account the cost of the drug and of medical devices necessary for its administration, based on the daily number of insulin injections. RESULTS - No further studies were found in addition to those included in a metaanalysis published by The Cochrane Library. On the basis of three eligible studies, insulin detemir was injected more frequently compared with glargine (weighted mean difference: 0.42 95% CI 0.14-0.69 injections/day). High heterogeneity was present in case of two endpoints: the incidence of overall hypoglycaemia per patient-year (I2=83%), and daily basal insulin dose in units per body weight (I2=94%). The reason for the high heterogeneity in hypoglycaemia rates was not identified by meta-regression; however, the difference in insulin doses per body weight was negatively associated with body weight (-0.027 IU/kg per 1 kg, 95%CI: -0.051; -0.004). On the basis of the present meta-analysis and meta-regression, our calculations suggest that treating an average weight (90 kg) patient with type 2 diabetes with insulin glargine would result in an annual cost reduction of 93 452 HUF compared with insulin detemir by employing gross public drug prices. CONCLUSION - On the basis of the available clinical evidence, insulin glargine might be a cost-saving alternative of insulin detemir in an average-weight patient with type 2 diabetes. In an era of scarce resources, the role of therapeutic alternatives offering cost savings with the same efficacy become more important. The generalisability of our conclusions might be influenced by potential differences in the manufacturers’ claw-back rate of detemir vs glargine insulin.]

Lege Artis Medicinae

[Titration of insulin glargin in type 2 diabetic patients treated with oral agents and with necessity of basal insulin in everyday medical practice ]


[INTRODUCTION - Early insulin treatment is a widely accepted option for combination glucose-lowering therapy, and its most common form is basal insulin supported oral therapy (BOT). Due to its 24-hour action and lack of peaks in plasma insulin concentrations, insulin glargine is an ideal choice for BOT. METHODS - We conducted a prospective, non-interventional study to evaluate the efficiency and safety of dose titration, the period of time necessary to reach the target fasting blood glucose level, and the changes in glargine insulin dose. The study group included patients with type 2 diabetes who had been treated with insulin glargine in BOT regimen for no longer than four weeks. The follow-up period was six months. RESULTS - During the study period, the mean fasting plasma glucose was decreased from 9.8 mmol/L to 6.7 mmol/L, the mean HbA1c level decreased from 8.8% to 7.3%, and the mean postprandial glucose level decreased from 11.5 mmol/L to 8.2 mmol/L. Mild hypoglycaemic episodes occurred in 6.5% of patients in the first 3 months and in 6.9% of patients between months 3 and 6. During the same periods, severe hypoglycaemic episodes occurred in 0.08% and 0.17% of patients, respectively. Both mean body weight and mean BMI decreased during the study period. The average daily dose of glargine continuously increased during the observation period from baseline 10.42 IU to 17.69 IU. DISCUSSION - In the study population, glargine therapy in BOT regimen significantly improved glycaemic control, while a slight but statistically significant reduction was observed in the patients’ body weight. The daily dose of insulin glargine increased during titration, and the therapy proved to be safe.]

Lege Artis Medicinae

[Type 2 diabetes in children and adolescents: early complications]


[INTRODUCTION - The prevalence of type 2 diabetes mellitus in children and adolescents is increasing worldwide. PATIENTS AND METHODS - Authors have investigated the prevalence of type 2 diabetes mellitus and of impaired glucose tolerance among the patients of the 1st Department of Pediatrics at the Semmelweis University between January 1989 and September 1998. RESULTS - During this period, 161 children with impaired glucose tolerance and 34 patients with type 2 diabetes mellitus were diagnosed. There was a female predominance. 53% of the patients were already in puberty. The majority of the patients were obese. Serum triglyceride and cholesterine levels exceeded normal values as compared to age matched healthy children. Ambulatory blood pressure monitoring revealed relative nocturnal hypertension. 35% of the patients also had microalbuminuria. CONCLUSION - In type 2 diabetes mellitus the early signs of late complications can be detected in the young. It reveals the importance of establishing the diagnosis of this disease as soon as possible.]

Lege Artis Medicinae


RODÉ Magdolna

[Obesity represents a major public health problem in both developed and developing countries having rapidly increased in prevalence in the past two decades. Childhood obesity is of particular concern. Two of its associated diseases require special attention; metabolic syndrome and type 2 diabetes one of its components that are increasingly diagnosed in childhood. A key to prevention and treatment is healthy lifestyle. The importance of education to healthy lifestyle from early childhood cannot be overemphasized.]

Image challenge

What do you see on the feet of the diabetic patient?